Burden of illness of follicular lymphoma and marginal zone lymphoma
Neerav Monga, Catherine Thiéblemont(Université Paris Cité), Loretta J. Nastoupil(The University of Texas MD Anderson Cancer Center), Peter O’Donovan(Genomics England), Joan Quigley(Boston University), Jamie Garside(Janssen (United Kingdom)), Lori Parisi(Janssen (United States)), Moira Hudson(Imperial Consultants), Christoph Tapprich(Janssen (Germany))
Cited by 32
Related Papers
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2018|3.7k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782
Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas
|Nature Medicine|2020|593
Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update
|Journal of Clinical Oncology|2018|574
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523